Last-Chance treatment offered to multiple myeloma patients
NCT ID NCT05161598
Summary
This program provided early access to the experimental drug teclistamab for patients with advanced multiple myeloma who had exhausted all standard treatment options. The program was designed for individuals who weren't eligible for clinical trials but had no other approved treatments available. It offered a potential treatment option for patients with relapsed or treatment-resistant disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.